ALB and thalassemia: Using the dominant genetic model, laboratory parameter analysis in children before and during HU therapy revealed significantly decreased ALT during HU therapy in carriers of α-thalassemia, while those without α-thalassemia presented significant increases in hemoglobin, hematocrit, MCV, MCH, HDL-c and albumin, as well as significant decreases in MCHC, neutrophils, reticulocytes and AST.